EMA green light new covid treatment

The European Union’s drugs regulator has approved the use of two monoclonal antibody therapies for COVID-19, paving the way for the use of Regeneron-Roche and Celltrion therapies amid a surge in cases on the continent.

In a statement released Thursday by the European Medicines Agency (EMA), the regulator recommended authorization of Regeneron-Roche treatment for adults and youth over the age of 12, while suggesting Celltrion should be used only in adults.

Regeneron-Roche’s Ronapreve and Celltrian’s Regkirona are the first monoclonal antibody treatments for Covid to be recommended for market authorization by the EMA’s Committee on Human Medicines (CHMP).

read more


FDA recalls lakhs of Covid test kits over false results

The treatments work by attaching themselves to a specific target – in this case, the spike protein in the coronavirus – to help ease symptoms and reduce the risk of hospitalization and death.

The approval comes as the winter months loom as EU member states wrestle with rising Covid cases, with many health services concerned as they struggle to deal with the combination of the coronavirus and seasonal flu infections. .

Think your friends would be interested? Share this story!

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous post Violence, insecurity and climate change drive 84 million people from their homes
Next post US envoy visiting Middle East allies ahead of Iran nuclear talks